Special Issue

Advances in Pleural and Peritoneal Mesothelioma

Message from the Guest Editor

Pleural and peritoneal mesotheliomas are rare, asbestos-related malignancies with an extremely poor prognosis and limited treatment options. Mesothelioma is a challenging tumor to diagnose and treat, and, currently, the histotype is the most reliable prognostic factor. However, recent studies on pleural mesothelioma have revealed genomic features that impact diagnosis, treatment response, and prognosis definition. Whereas there is data available regarding molecular characterization of peritoneal mesothelioma. Molecular studies of both pleural and peritoneal mesothelioma are strongly warranted to define biomarkers useful to improve clinical practice. This Special Issue welcomes original articles, reviews, and meta-analyses underlying advances in pleural and peritoneal mesothelioma from genetic landscape to treatment. I look forward to receiving your contributions.

Guest Editor

Dr. Rossella Bruno

Unit of Pathological Anatomy, University Hospital of Pisa, Via Roma 67, 56126 Pisa, Italy

Deadline for manuscript submissions

closed (10 November 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/226122

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

